Altrius Capital Management Inc Purchases 11,232 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Altrius Capital Management Inc boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 21.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 64,212 shares of the biopharmaceutical company’s stock after acquiring an additional 11,232 shares during the period. Altrius Capital Management Inc’s holdings in Gilead Sciences were worth $4,406,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in the business. CarsonAllaria Wealth Management Ltd. increased its holdings in shares of Gilead Sciences by 198.3% in the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 238 shares during the period. Palisade Asset Management LLC acquired a new stake in Gilead Sciences in the first quarter worth about $29,000. Sachetta LLC acquired a new stake in Gilead Sciences in the 4th quarter worth approximately $30,000. Financial Connections Group Inc. acquired a new position in Gilead Sciences during the 2nd quarter valued at approximately $34,000. Finally, Frank Rimerman Advisors LLC purchased a new position in shares of Gilead Sciences in the fourth quarter worth $36,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction on Monday, July 1st. The stock was sold at an average price of $68.63, for a total transaction of $137,260.00. Following the transaction, the insider now owns 96,380 shares in the company, valued at approximately $6,614,559.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the sale, the insider now owns 96,380 shares of the company’s stock, valued at approximately $6,614,559.40. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Johanna Mercier sold 5,490 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total transaction of $406,150.20. Following the sale, the insider now directly owns 114,979 shares in the company, valued at approximately $8,506,146.42. The disclosure for this sale can be found here. Insiders sold a total of 36,847 shares of company stock worth $3,002,940 in the last three months. 0.16% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on GILD shares. Royal Bank of Canada upped their target price on Gilead Sciences from $72.00 to $74.00 and gave the company a “sector perform” rating in a research report on Wednesday, September 4th. Evercore ISI raised Gilead Sciences to a “strong-buy” rating in a report on Friday, August 9th. Raymond James raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 price target for the company in a research report on Monday, July 8th. Piper Sandler reissued an “overweight” rating and issued a $95.00 price objective on shares of Gilead Sciences in a report on Wednesday, September 11th. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $70.00 price target on shares of Gilead Sciences in a research note on Monday. Twelve research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus price target of $82.06.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $83.89 on Thursday. The company has a market cap of $104.51 billion, a P/E ratio of 233.03, a P/E/G ratio of 2.80 and a beta of 0.18. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $87.86. The company’s 50-day moving average price is $76.40 and its 200-day moving average price is $71.09. The company has a current ratio of 1.14, a quick ratio of 0.95 and a debt-to-equity ratio of 1.18.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping analysts’ consensus estimates of $1.61 by $0.40. The business had revenue of $6.95 billion for the quarter, compared to analyst estimates of $6.64 billion. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. On average, sell-side analysts forecast that Gilead Sciences, Inc. will post 3.78 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 27th. Shareholders of record on Friday, September 13th will be paid a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 3.67%. The ex-dividend date of this dividend is Friday, September 13th. Gilead Sciences’s dividend payout ratio (DPR) is currently 855.56%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.